BidaskClub upgraded shares of China Biologic Products (NASDAQ:CBPO) from a strong sell rating to a sell rating in a report released on Tuesday morning.

Separately, Zacks Investment Research upgraded shares of China Biologic Products from a sell rating to a hold rating in a research note on Monday, February 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of Hold and a consensus target price of $137.50.

Shares of China Biologic Products (NASDAQ:CBPO) opened at $79.73 on Tuesday. China Biologic Products has a 12 month low of $72.21 and a 12 month high of $120.46. The firm has a market cap of $2,648.77, a PE ratio of 17.81, a price-to-earnings-growth ratio of 1.01 and a beta of 1.67.

Large investors have recently modified their holdings of the company. Comgest Global Investors S.A.S. raised its position in shares of China Biologic Products by 135.0% in the 3rd quarter. Comgest Global Investors S.A.S. now owns 356,252 shares of the biopharmaceutical company’s stock valued at $32,872,000 after buying an additional 204,649 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in shares of China Biologic Products in the 3rd quarter valued at approximately $795,000. Bank of New York Mellon Corp raised its position in shares of China Biologic Products by 30.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 762,784 shares of the biopharmaceutical company’s stock valued at $70,380,000 after buying an additional 176,325 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of China Biologic Products by 4.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 61,404 shares of the biopharmaceutical company’s stock valued at $6,945,000 after buying an additional 2,845 shares in the last quarter. Finally, Wasatch Advisors Inc. raised its position in shares of China Biologic Products by 66.1% in the 4th quarter. Wasatch Advisors Inc. now owns 228,373 shares of the biopharmaceutical company’s stock valued at $17,989,000 after buying an additional 90,891 shares in the last quarter. Institutional investors own 52.44% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “China Biologic Products (CBPO) Upgraded by BidaskClub to Sell” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.thecerbatgem.com/2018/02/14/china-biologic-products-cbpo-upgraded-by-bidaskclub-to-sell.html.

About China Biologic Products

China Biologic Products Holdings, Inc is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company’s products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.